ASO Visual Abstract: Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
Titel:
ASO Visual Abstract: Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)